PUMA BIOTECHNOLOGY INC
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
| ITEM 9B. | OTHER INFORMATION |
|---|
Trading Plans
During the fiscal quarter ended* December 31, 2023,our directors and officers (as defined in Rule16a*-1(f) under the Exchange Act) who adopted or terminated contracts, instructions, written plans or arrangements for the purchase or sale of our securities are set forth in the table below:
| Trading Arrangement | ||||||
| Name and Title | Action | Date | Rule 10b5-1* | Non-Rule 10b5-1** | Total Shares of Common Stock to be Sold | Expiration Date |
|---|---|---|---|---|---|---|
| Brian Stuglik, Board Member | Adopt | December 16, 2023 | X | Up to 9,900 shares | June 30, 2024 | |
| Troy Wilson, Board Member | Adopt | December 15, 2023 | X | Up to 27,000 shares | June 30, 2024 | |
| Jay Moyes, Board Member | Adopt | December 17, 2023 | X | Up to 22,000 shares | June 30, 2024 | |
| Adrian Senderowicz, Board Member | Adopt | December 15, 2023 | X | Up to 27,000 shares | June 30, 2024 | |
- Intended to satisfy the affirmative defense of Rule10b5-1(c)
Not intended to satisfy the affirmative defense of Rule10b5-1(c)
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.